Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End Business Results for 2021 and Host Conference Call on March 9, 2022

Rhea-AI Summary

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will announce its fourth quarter and year-end 2021 results on March 9, 2022. Following the report, a conference call will be held to discuss the company’s progress and goals for the upcoming year at 4:30 p.m. ET. Investors can join via dial-in or webcast. Mirum focuses on rare diseases, with its approved treatment, LIVMARLI® for cholestatic pruritus in Alagille syndrome. The company is advancing its pipeline with clinical trials for conditions affecting pediatric and adult liver diseases.

Positive

• Mirum Pharmaceuticals has an approved medication, LIVMARLI®, enhancing its credibility in the biopharmaceutical space.
• The company is actively developing a late-stage pipeline targeting critical liver diseases.
• Recent submissions for Marketing Authorization to the European Medicines Agency suggest potential market expansion.

Negative

• None.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2021 results on Wednesday, March 9, 2022. That same day, Mirum will host a conference call to discuss the company’s progress and achievements in 2021 as well as priorities for 2022.

Conference call details:
Wednesday, March 9, 2022
4:30 p.m. ET / 1:30 p.m. PT

Dial-in:
U.S./Toll-Free: 833-927-1758
International: 646-904-5544
Passcode: 521837

You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome.

Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.

Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220302005442/en/

Media Contact:

Erin Murphy

media@mirumpharma.com

Investor Contacts:

Ian Clements, Ph.D.

ir@mirumpharma.com

Sam Martin

Argot Partners

ir@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

When will Mirum Pharmaceuticals report its 2021 results?

Mirum Pharmaceuticals will report its 2021 results on March 9, 2022.

What is the significance of the upcoming conference call for Mirum Pharmaceuticals?

The conference call will address Mirum's achievements in 2021 and priorities for 2022.

What is LIVMARLI® and its relevance to Mirum Pharmaceuticals?

LIVMARLI® is an approved medication by Mirum for treating cholestatic pruritus in patients with Alagille syndrome.

How is Mirum Pharmaceuticals expanding its treatment options?

Mirum is advancing clinical trials for liver diseases and submitted a Marketing Authorization Application to the European Medicines Agency.